The aim of this review is to analyze and describe the current landscape of bladder cancer
diagnostic and surveillance biomarkers. We researched the literature from 2016 to …

Patients with non-muscle invasive bladder cancer (NMIBC) have high recurrence and
progression rates in spite of tumor resection and adjuvant instillation therapy. To detect …

Background Limited evidence exists regarding the cost and health-related quality of life
(HRQoL) effects of non–muscle-invasive bladder cancer (NMIBC) recurrence and …

Objective To determine patient experience and perception following a diagnosis of non‐
muscle‐invasive bladder cancer (NMIBC). Patient and methods Patients were part of a …

Simple Summary Non-muscle invasive bladder cancer (NMIBC) accounts for three quarters
of newly detected bladder tumors. NMIBC can be treated conservatively with a bladder …

Background To evaluate the diagnostic accuracy of computed tomography-urography (CTU)
to rule out urinary bladder cancer (UBC) and whether patients thereby could omit …

Background Blood-based biomarkers (liquid biopsy) are increasingly used in precision
oncology. Yet, little is known about cancer patients' perspectives in clinical practice. We …

Objective To determine the acceptability of a non‐invasive urinary biomarker test in place of
conventional flexible cystoscopy for the diagnosis of bladder cancer in patients referred to a …

Background Hematuria is a cardinal symptom of urinary tract cancer and would require
further investigations. Objective To determine the ability of renal bladder ultrasound (RBUS) …

Introduction Cytology and cystoscopy are used to detect urothelial carcinoma (UC), but
together they still fail to detect some UC cases and are not suitable for screening …